Rosuvastatin has Slight Edge Over Atorvastatin in reduction of all cause mortality among patients with dislipedemia, suggests study
Researchers have found that while rosuvastatin and atorvastatin are two of the most commonly prescribed drugs in managing cholesterol, rosuvastatin may offer some additional benefit over atorvastatin in the context of reducing all-cause mortality. A recent study was conducted by Zhou and colleagues published in the journal Annals of Internal Medicine. This study fills this gap by comparing the outcome of patients who were exposed to rosuvastatin and atorvastatin in two large databases: the China Renal Data System (CRDS) and UK Biobank (UKB).
The aim of the study was to compare the real-world effectiveness and safety profiles of rosuvastatin and atorvastatin, with a focus on all-cause mortality, major cardiovascular events, and statin-related adverse effects. This was an active comparator cohort study utilizing the target trial emulation research approach. The latter emulates the design of a randomized controlled trial. This study included data from 285,680 adults newly prescribed rosuvastatin or atorvastatin within the CRDS and UKB databases. To limit selection bias, 1:1 multilevel propensity score matching was applied to harmonize characteristics between the two patient groups. After this matching, Cox proportional hazards regressions were used to estimate the primary outcome of all-cause mortality as well as any other adverse events.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.